Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07360314 · ClinicalTrials.gov registry record · Phase 1
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
- 8
- Study locations
NCT07360314 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 138 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (30% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT07360314, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
Conditions Studied
Interventions
- DRUG M7437
Study Locations (8)
Other
- Princess Margaret Cancer Centre - Toronto
- BC Cancer - Vancouver - BC Cancer Agency - Vancouver
- National Cancer Center Hospital - Tokyo
- NEXT Madrid - Hospital Universitario Quironsalud Madrid - Madrid
Texas
- NEXT Houston - Galveston
- NEXT Oncology - PARENT - San Antonio
Connecticut
- Yale University - Yale University School of Medicine - New Haven
North Carolina
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2029-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07360314
The ClinicalTrials.gov registry entry for NCT07360314 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (30% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which M7437 is the first listed.
NCT07360314 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07360314 about?
NCT07360314 is a clinical study titled "Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors". The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-...
What is the current status of trial NCT07360314?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2026-02-13. Estimated completion is 2029-03-28.
What conditions does trial NCT07360314 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07360314?
The interventions under investigation include: M7437 (DRUG).
Who is sponsoring clinical trial NCT07360314?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07360314 being conducted?
This trial has 8 study locations across Connecticut, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.